G
Gert J. Ossenkoppele
Researcher at VU University Medical Center
Publications - 255
Citations - 12256
Gert J. Ossenkoppele is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 48, co-authored 255 publications receiving 10571 citations. Previous affiliations of Gert J. Ossenkoppele include Vanderbilt University Medical Center.
Papers
More filters
Journal ArticleDOI
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Hartmut Döhner,Elihu H. Estey,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Alan Kenneth Burnett,Hervé Dombret,Pierre Fenaux,David Grimwade,Richard A. Larson,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Bob Löwenberg,Clara D. Bloomfield +18 more
TL;DR: An international expert panel is provided to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials.
Journal ArticleDOI
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M. Kantarjian,Francis J. Giles,Norbert Gattermann,Kapil N. Bhalla,Giuliana Alimena,Francesca Palandri,Gert J. Ossenkoppele,Franck E. Nicolini,Stephen G. O'Brien,Mark R. Litzow,Ravi Bhatia,Francisco Cervantes,Ariful Haque,Yaping Shou,Debra Resta,Aaron Weitzman,Andreas Hochhaus,Philipp le Coutre +17 more
TL;DR: Nilotinib is highly active and safe in patients with CML-CP after imatinib failure or intolerance and was effective in patients harboring BCR-ABL mutations associated with imatinIB resistance (except T315I), and also in Patients with a resistance mechanism independent of B CR-ABl mutations.
Journal ArticleDOI
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Gerrit Jan Schuurhuis,Michael Heuser,Sylvie D. Freeman,Marie C. Béné,Francesco Buccisano,Jacqueline Cloos,David Grimwade,Torsten Haferlach,Robert Kerrin Hills,Christopher S. Hourigan,Jeffrey L. Jorgensen,Wolfgang Kern,Francis Lacombe,Luca Maurillo,Claude Preudhomme,Bert A. van der Reijden,Christian Thiede,Adriano Venditti,Paresh Vyas,Brent L. Wood,Roland B. Walter,Roland B. Walter,Konstanze Döhner,Gail J. Roboz,Gert J. Ossenkoppele +24 more
TL;DR: The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRd in clinical practice.
Journal ArticleDOI
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Matthew S. Zabriskie,Christopher A. Eide,Christopher A. Eide,Srinivas K. Tantravahi,Nadeem A. Vellore,Johanna Estrada,Franck E. Nicolini,Hanna Jean Khoury,Richard A. Larson,Marina Konopleva,Jorge E. Cortes,Hagop M. Kantarjian,Elias J. Jabbour,Steven M. Kornblau,Jeffrey H. Lipton,Delphine Rea,Leif Stenke,Gisela Barbany,Thoralf Lange,Juan Carlos Hernández-Boluda,Gert J. Ossenkoppele,Richard D. Press,Charles Chuah,Stuart L. Goldberg,Meir Wetzler,François Xavier Mahon,Gabriel Etienne,Michele Baccarani,Simona Soverini,Gianantonio Rosti,Philippe Rousselot,Ran Friedman,Marie Deininger,Kimberly R. Reynolds,William L. Heaton,Anna M. Eiring,Anthony D. Pomicter,Jamshid S. Khorashad,Todd W. Kelley,Riccardo Baron,Brian J. Druker,Brian J. Druker,Michael W. Deininger,Thomas O'Hare +43 more
TL;DR: These findings demonstrate that BCR-ABL1 compound mutants confer different levels of TKI resistance, necessitating rational treatment selection to optimize clinical outcome, and in vitro resistance profiling was predictive of treatment outcomes in Ph(+) leukemia patients.
Journal ArticleDOI
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
Miguel A. Sanz,Pau Montesinos,Chelo Rayon,Alexandra Holowiecka,Javier de la Serna,Gustavo Milone,Elena de Lisa,Salut Brunet,Vicente Rubio,José M. Ribera,Concha Rivas,Isabel Krsnik,Juan Bergua,José González,Joaquín Díaz-Mediavilla,R Rojas,Félix Manso,Gert J. Ossenkoppele,José D. González,Bob Löwenberg +19 more
TL;DR: The lower dose of mitoxantrone resulted in a significant reduction of toxicity and hospital stay while maintaining the antileukemic activity, and the combination of ATRA, idarubicin, and cytarabine for high-risk acute promyelocytic leukemia significantly reduced the relapse rate in this setting.